REG - IXICO plc - Results of AGM

IXICOAnnouncement

23/01/2026 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260123:nRSW2335Qa&default-theme=true

RNS Number : 2335Q  IXICO plc  23 January 2026

 

23 January 2026

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and
biomarker analytics, using its AI-driven platform to help advance drug
development in neurological disorders, announces that all resolutions put
forward to its Annual General Meeting held earlier today were duly passed and
the votes cast were as follows:

 

     RESOLUTION                                         VOTES       %        VOTES     %      VOTES       % ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1   Reports and Accounts                               58,472,204  99.99%   6,000     0.01%  58,478,204  63.10        1,700
 2a  Re-election of Bram Goorden                        58,465,677  99.99%   6,600     0.01%  58,472,277  63.10        7,627
 2b  Re-election of Grant Nash                          58,465,677  99.99%   6,600     0.01%  58,472,277  63.10        7,627
 2c  Re-election of Mark Warne                          58,465,677  99.99%   6,600     0.01%  58,472,277  63.10        7,627
 2d  Re-election of Dr Dipti Amin                       58,465,677  99.99%   6,600     0.01%  58,472,277  63.10        7,627
 2e  Re-election of Kate Rogers                         58,465,677  99.99%   6,600     0.01%  58,472,277  63.10        7,627
 3   Re-appointment of  Moore Kingston Smith Auditors   58,475,004  100.00%  2,800     0.00%  58,477,804  63.10        2,100
 4   Allotment of Securities                            58,475,336  100.00%  1,800     0.00%  58,477,136  63.10        2,768
 5   * Disapply Pre-Emption Provisions                  58,354,629  99.79%   122,507   0.21%  58,477,136  63.10        2,768

* Special Resolution

For the purposes of section 341 of the Companies Act 2006, IXICO plc's total
issued share capital with voting rights as at 6.30pm on 22 January 2026, being
the time at which a shareholder had to be registered in the Company's register
of members in order to attend and vote at the AGM, was 92,668,598 ordinary
shares.

Please note that a 'vote withheld' is not a vote under English Law and is not
counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.

 

 

 

For further information please contact:

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEDFWDEMSESF



            Copyright 2019 Regulatory News Service, all rights reserved